Role of Intestinal Microbiota and Metabolites in Inflammatory Bowel Disease

Did you know? Inflammatory bowel disease (IBD)—a group of chronic gut conditions including Crohn’s disease (CD) and ulcerative colitis (UC)—is no longer just a “Western problem.” Cases are surging in Asia, the Middle East, and Latin America, with some countries seeing a 10x increase in just 20 years. While diet, genes, and immune system dysfunction play roles, scientists are increasingly pointing to a “forgotten” factor: your gut microbiota—the trillions of bacteria living in your intestines.

Researchers from Shanxi Provincial People’s Hospital in China, led by Prof. Jun-Ping Wang, reviewed the latest science linking gut bacteria and their byproducts to IBD in a 2019 study published in the Chinese Medical Journal. Here’s what you need to know about how your gut’s microbial community affects IBD—and how this research could transform treatment for millions.

Understanding IBD: A Global Health Crisis

IBD causes chronic inflammation and damage to the gastrointestinal tract, leading to symptoms like diarrhea, abdominal pain, and weight loss. Once concentrated in Western nations, it’s now a global epidemic:

In Iran, a middle-income country, IBD rates jumped 400% between 2000 and 2016.
In Asia, cases have risen by 7% annually since 2010.

While genetics and diet contribute, the gut microbiota—often called the “second brain” of the body—is emerging as one of the most critical environmental triggers.

Gut Microbiota: The “Hidden” Player in IBD

Your gut hosts over 1,000 bacterial species—more than the number of cells in your body. These bacteria do far more than digest food: they protect against pathogens, build your intestinal lining, and regulate your immune system. When this community is balanced (eubiosis), your gut stays healthy. When it’s imbalanced (dysbiosis), problems like IBD arise.

The Chinese study confirms a key finding: IBD patients have a drastically different gut microbiota than healthy people. Here’s how:

1. Less Bacterial Diversity

Healthy guts are like microbial “rainforests”—diverse and resilient. In IBD, this diversity shrinks:

Firmicutes and Bacteroidetes—the two most abundant bacterial phyla (large groups)—are depleted by 30–50%.
Harmful phyla like Proteobacteria (including E. coli) and Actinobacteria multiply.

Less diversity means your gut is less able to fight infections and maintain balance.

2. Fewer “Friendly” Bacteria

Probiotics—live bacteria that benefit health—are in short supply in IBD patients. Two key types stand out:

Faecalibacterium prausnitzii: This bacteria produces butyrate, a fatty acid that feeds gut cells and reduces inflammation. It’s 50–70% less common in IBD patients.
Bacteroides: These bacteria break down fiber and make vitamins. Levels are low even when the gut isn’t inflamed.

3. More Harmful Bacteria

While no single “IBD bacteria” exists, certain pathogens are overrepresented in IBD:

Adherent-invasive E. coli (AIEC): Sticks to and invades gut cells, triggering inflammation. Found in 30–40% of CD patients.
Mycobacterium avium paratuberculosis (MAP): Linked to Crohn’s disease, it infects the small intestine and causes chronic inflammation.
Fusobacterium nucleatum: Invades colon cells and is 2–3x more common in inflamed IBD tissue.

Can Gut Bacteria Diagnose or Treat IBD?

Scientists are exploring two game-changing uses for gut microbiota:

Gut Bacteria as a “Biomarker”

Your fecal bacteria could soon replace invasive tests like colonoscopies:

Diagnosis: Tests like GA-map dysbiosis testing analyze fecal microbes to spot IBD-linked imbalances.
Disease monitoring: Fecal profiles can tell doctors if CD is active or in remission—no needles or scopes needed.
Treatment response: High levels of Faecalibacterium prausnitzii predict better results with ustekinumab, a drug for treatment-resistant CD.

Treating IBD with “Good” Bacteria

Two strategies are gaining traction:

Probiotics: While not a cure, probiotics help keep IBD in remission. The VSL#3 mix (8 strains) is especially effective for UC. Combining probiotics with prebiotics (fiber that feeds good bacteria) works even better.
Fecal Microbiota Transplantation (FMT): Swaps a sick person’s gut bacteria with a healthy donor’s. It’s highly effective for IBD patients with Clostridium difficile infection (a severe gut bug) and may prevent relapse after surgery. However, it’s less consistent for non-infected IBD—1 in 4 patients experience a flare-up.

Metabolites: The “Messengers” Between Bacteria and IBD

Bacteria don’t just live in your gut—they communicate with your body using metabolites (small molecules). Two metabolites are critical for IBD:

Short-Chain Fatty Acids (SCFAs)

SCFAs are made when bacteria ferment fiber. The most important is butyrate, which:

Feeds 60–70% of your gut cells.
Strengthens the intestinal barrier (preventing “leaky gut”).
Reduces inflammation by calming immune cells.

IBD patients have 30–50% less butyrate because Faecalibacterium prausnitzii (a top producer) is missing. Oral butyrate supplements may boost mesalazine (a common IBD drug) effectiveness for UC.

Tryptophan

Tryptophan—an essential amino acid from turkey, eggs, and tofu—is broken down by bacteria into compounds like indoles and kynurenine. These:

Regulate the immune system (kynurenine calms overactive T cells).
Protect the gut barrier.

In IBD, tryptophan metabolism is imbalanced: indoles (anti-inflammatory) are low, while kynurenine (pro-inflammatory) is high. This worsens gut damage.

How Bacteria and Metabolites Drive IBD

Two key mechanisms link gut bacteria to IBD:

Leaky Gut: Friendly bacteria build tight junctions (the “glue” holding gut cells together). When they’re missing, junctions weaken—allowing bacteria and toxins to leak into the bloodstream. This triggers an immune response.
Overactive Immune System: Your immune system normally ignores friendly bacteria. In IBD, it mistakes them for pathogens. SCFAs usually calm this response, but low SCFA levels let inflammation run wild.

What’s Next? The Future of Gut-Based IBD Research

While the link between gut bacteria and IBD is clear, gaps remain:

Which bacteria matter most? No single “IBD microbe” has been identified—researchers need to find which strains drive inflammation.
Personalized treatments: Gut bacteria vary by person—probiotics or FMT that work for one patient may fail another.
Diet and lifestyle: How do antibiotics, stress, or processed food interact with gut bacteria to trigger IBD?

Conclusion

IBD is a complex disease, but one truth is clear: your gut bacteria and their metabolites are not just “passengers”—they’re active players in causing and worsening inflammation. From using fecal bacteria to diagnose IBD to treating it with probiotics or FMT, gut-based therapies are opening new doors for patients.

As Prof. Wang’s team notes: “The future of IBD research lies in restoring balance to the gut microbiota.” For millions living with IBD, that future can’t come soon enough.

Original Study: Dong LN, Wang M, Guo J, Wang JP. Role of intestinal microbiota and metabolites in inflammatory bowel disease. Chinese Medical Journal 2019;132:1610–1614. doi: 10.1097/CM9.0000000000000290

Was this helpful?

0 / 0